| For immediate release | 27 June 2024 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to Directors
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Board has issued options over 906,862 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to Nick Sedgwick, pursuant to the Company's Long-Term Incentive Plan 2019.
The awards have been granted at nil-cost and become exercisable on 24 June 2027 subject always to continued employment and the satisfaction of performance conditions based on EPS, TSR and ROCE targets.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging managerial responsibilities.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Mr Nick Sedgwick | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer - PDMR | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Alliance Pharma plc | |
| b) | Legal Entity Identifier | N/A | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1.0 pence each
ISIN: GB0031030819 | |
| b) | Nature of the transaction | Grant of Options | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Exercise Price (p) | No. of share options |
| Nil | 906,862 | ||
| | | ||
|
| |||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total | Grant of 906,862 options to acquire ordinary shares of 1 pence each at nil-cost.
| |
| f) | Date of the transaction | 24 June 2024 | |
| g) | Place of the transaction | Outside of trading venue | |
For further information:
| Alliance Pharma plc | + 44 (0)1249 466966 |
| Head of Investor Relations: Cora McCallum | + 44 (0)1249 705168 |
|
| |
| www.alliancepharma.co.uk | |
| Buchanan | + 44 (0)20 7466 5000 |
| Mark Court / Sophie Wills | |
| | |
|
| |
| Numis Securities Limited (Nominated Adviser and Joint Broker) | + 44 (0)20 7260 1000 |
| Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah | |
|
| |
| Investec Bank plc (Joint Broker) | + 44 (0)20 7597 5970 |
| Patrick Robb / Maria Gomez de Olea | |
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.